Fzata, Inc.
Wednesday, June 05, 2024
Start-Up Stadium Session
Platform for Therapeutics
5B
Company Description: Fzata (fzata.com) has solved the oral biologics problem with the BIoPYM platform. Live yeast micro-factories make and secrete biologic therapeutic in the GI. Direct GI targeting avoids anti-drug antibody and systemic tox common to biologics like Humira which suffer upto a 50% discontinuation rate. We are an NIH Seed company with $17M non-dilutive. First in human clinical study will be 2024 for FZ002 c diff program fully supported by NIH. We are now raising seed $10M to support FZ006 IBD program. FZ006 will be the first oral anti-TNFalpha for IBD and also the first anti-TNFalpha for the mild-moderate IBD population. This is a multi-billion dollar market in the US alone and a huge unmet medical need.
Company Website:
http://www.fzata.com
Company HQ City
Halethorpe
Company HQ State
Maryland
Company HQ Country
United States
CEO/Top Company Official
Zhiyong Yang, CEO
Primary Speaker